by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E

Slides:

Advertisements

Similar presentations

January 6. January 7 January 8 January 9 January 10.

Advertisements

Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome by Jacob H. Rand,

Mapping the interaction between factor VIII and von Willebrand factor by electron microscopy and mass spectrometry by Po-Lin Chiu, George M. Bou-Assaf,

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,

Prognostication of survival using cardiac troponins and N- terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing.

Determination of acute lung injury after repeated platelet transfusions by Laurence Corash, Jin Sying Lin, Claire D. Sherman, and Joseph Eiden Blood Volume.

Late survival in abdominal aortic aneurysm patients: The role of selective myocardial revascularization on the basis of clinical symptoms Martha M. Reigel,

by Angela Dispenzieri, A. Keith Stewart, Asher Chanan-Khan, S

Treatment of Immunoglobulin Light Chain Amyloidosis

by Robert F. Todd, Scott D. Gitlin, Linda J. Burns, and

Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts by Boglarka Gyurkocza,

by Toru Takahashi, Toshiaki Yujiri, and Yukio Tanizawa

Platelet Antibody Testing in Idiopathic Thrombocytopenic Purpura

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,

Dasatinib induces complete remission in a patient with primary cerebral involvement of B-cell chronic lymphocytic leukemia failing chemotherapy by Georg.

Utility of factor X concentrate for the treatment of acquired factor X deficiency in systemic light-chain amyloidosis by Shameem Mahmood, Julie Blundell,

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome by Anita D'Souza, Suzanne.

Detection of vascular endothelial growth factor in AIDS-related primary effusion lymphomas by Yoshiyasu Aoki, Giovanna Tosato, Yoshihiro Nambu, Aikichi.

by Rafael Fonseca, Richard J. Bailey, Gregory J. Ahmann, S

Current Therapy for Multiple Myeloma

Critiquing Cryos by Morie Gertz Blood Volume 111(11):

Symptomatic and Incidental Venous Thromboembolic Disease Are Both Associated With Mortality In Patients With Prostate Cancer by Shruti Chaturvedi, Surbhi.

Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib by Preetesh Jain, Michael Keating, William Wierda, Zeev Estrov, Alessandra.

by Satish Gopal, William A. Wood, Stephanie J. Lee, Thomas C

Effect of short-term interferon therapy on the outcome of subsequent HLA-identical sibling bone marrow transplantation for chronic myelogenous leukemia:

by Petri Salven, Lasse Teerenhovi, and Heikki Joensuu

Autologous Transplantation Therapy for Chronic Myelogenous Leukemia

Fusion genes in cord blood

Genetic sequence analysis of inherited bleeding diseases

Comparison of the efficacy of rabbit and horse antithymocyte globulin for the treatment of severe aplastic anemia in children by Ayami Yoshimi, Charlotte.

Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system by.

What is a true ALCL? by Wolfram Klapper Blood Volume 124(9):

Relationship of p53, bcl-2, and Tumor Proliferation to Clinical Drug Resistance in Non-Hodgkin's Lymphomas by Wyndham H. Wilson, Julie Teruya-Feldstein,

by Nelson Leung, Samih H. Nasr, and Sanjeev Sethi

Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma by Rishi K.

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Stage C or not stage C…? by Claire Dearden Blood

Primary testicular lymphoma

Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma by Mohammed A. Aljama, M. Hasib Sidiqi, Arjun.

by Michael F. Leahy, and J. Harvey Turner

Does Helicobater pylori initiate or perpetuate immune thrombocytopenic purpura? by Marc Michel, Nichola Cooper, Christelle Jean, Christine Frissora, and.

Response of Primary Hepatic Amyloidosis to Melphalan and Prednisone: A Case Report and Review of the Literature MORIE A. GERTZ, M.D., ROBERT A. KYLE,

by John J. Strouse, Megan E. Reller, David G

Sumit Madan, MD, Robert A. Kyle, MD, Philip R. Greipp, MD

Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma by Angela Dispenzieri,

by Martin S. Tallman, Donna Neuberg, John M. Bennett, Christopher J

Amyloidosis: 2008 BMT Tandem Meetings (February 13-17, San Diego)

Volume 73, Issue 11, Pages (June 2008)

Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia by Philip.

Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines.

Amyloidosis: Recognition, Confirmation, Prognosis, and Therapy

by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc

Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines Stephen.

Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines

Distribution of average number of joint bleeds across factor activity level by age groups for patients with hemophilia B. In the boxplots, the central.

Predicted number of joint bleeds according to factor activity level and age group for patients with hemophilia A or B based on a regression model. Predicted.

Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma by Nidhi Tandon, Surbhi Sidana, S. Vincent Rajkumar,

by Giovanni Palladini, and Giampaolo Merlini

by Wendy Lim, Sara K. Vesely, and James N. George

Treatment versus Transplant for Challenging Hematologic Disorders

Treatment algorithm for management of CRS based on the revised CRS grading system. Treatment algorithm for management of CRS based on the revised CRS grading.

Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.

Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015 by Evaren E. Page, Johanna A.

Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis by Mohammed A. Aljama, M. Hasib Sidiqi,

How I treat cryoglobulinemia

Mesenchymal Stem Cell-Derived Vesicles Reverse Hematopoietic Radiation Damage by Sicheng Wen, Laura R Goldberg, Mark S Dooner, John L Reagan, and Peter.

In Memoriam: E. Donnall Thomas

Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia

Cold agglutinin disease

Presentation transcript:

Long-Term Survival (10 Years or More) in 30 Patients With Primary Amyloidosis by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E. Witzig, John A. Lust, Martha Q. Lacy, and Terry M. Therneau Blood Volume 93(3):1062-1066 February 1, 1999 ©1999 by American Society of Hematology

Survival for 810 patients with systemic amyloidosis seen at Mayo Clinic between January 1, 1966 and March 1, 1987. Survival for 810 patients with systemic amyloidosis seen at Mayo Clinic between January 1, 1966 and March 1, 1987. Robert A. Kyle et al. Blood 1999;93:1062-1066 ©1999 by American Society of Hematology

Status of 685 patients with primary systemic amyloidosis seen at Mayo Clinic within 6 months of diagnosis, by age. Status of 685 patients with primary systemic amyloidosis seen at Mayo Clinic within 6 months of diagnosis, by age. Robert A. Kyle et al. Blood 1999;93:1062-1066 ©1999 by American Society of Hematology